NeuPath Health (NPTH) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 total revenue of $18.9 million, up 11% year-over-year, and $36.4 million for the first half, up 10% year-over-year.

• Adjusted EBITDA reached $1.3 million for Q2 and $2.2 million for the first half, marking the 22nd consecutive quarter of positive adjusted EBITDA.

• Net debt decreased by 37% versus June 30, 2023, reflecting improved cash flows and financial discipline.

• Focus on core clinics business and facility investments continues to drive operational improvements.

Financial highlights

• Q2 2024 total revenue was $18.9 million, up from $17.1 million in Q2 2023; six-month revenue was $36.4 million, up from $33.2 million.

• Adjusted EBITDA for Q2 2024 was $1.3 million, up 30% year-over-year; six-month adjusted EBITDA was $2.2 million, up 22%.

• Gross margin improved to 20.0% in Q2 2024 from 18.8% in Q2 2023; six-month gross margin rose to 19.3% from 18.4%.

• Net and comprehensive income for Q2 2024 was $362,000, up from $46,000 in Q2 2023.

Outlook and guidance

• Management expects continued operational improvements and further investments in facilities over the next few quarters.

• Growth opportunities and enhanced patient service remain strategic priorities.